A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 850 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... May 30, 2022 EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp August 13, 2020 One year on: How has COVID-19 affected cancer services? May 14, 2021 FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... April 8, 2026 Load more HOT NEWS How to Support a Spouse or Partner During Cancer Treatment by... Glioblastoma Study Highlights Sex Differences in Brain Cancer 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord... New Research on Treating Hormone Receptor-Positive Breast Cancer From SABCS 2020
